Data di Pubblicazione:
2021
Abstract:
Patients with relapsed/refractory Hodgkin lymphoma (R/R HL) experience high response rates upon anti-PD1 therapy. In these patients, the optimal duration of treatment and the risk of relapse after anti-PD1 discontinuation are unknown.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Biomarkers; Checkpoint inhibitors; Hodgkin lymphoma; Immunotherapy
Elenco autori:
Manson, G; Brice, Pauline; Herbaux, C; Silva, Mg; Bouabdallah, K; Deau, B; Bouteloup, J; Schiano, Jm; Nicolas-Virelizier, E; Maerevoet, M; Ghesquieres, H; Stamatoullas, A; Antier, C; Carlo-Stella, Carmelo; de Charette, M; Poizeau, F; Dercle, L; Houot, Roch
Link alla scheda completa:
Pubblicato in: